▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #775 by analyst upside · 2026-08-13
MNKD
MannKind Corporation
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+107.0%
implied upside to consensus target
Current Price $3.85
Consensus Target $7.97
Bull Target $13.0
Bear Target $4.75
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
7
Hold
1
Sell
0
52-Week Low $2.23
52-Week High $6.51
YTD Return -31.3%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E 30.2x
EPS (TTM) $-0.15
PEG Ratio 4.39
Dividend Yield N/A
Revenue (TTM) $394M
Profit Margin -11.1%
52-WEEK RANGE
52-Week Low $2.23
52-Week High $6.51
Current Price $3.85
Bear Target $4.75
Bull Target $13.0
● Now $3.85 ● Target $7.97
TRADING DATA
Avg Volume 5.2M
YTD Return -31.3%
Analyst Count 8
Consensus Buy
Upside to Target +107.0%
Last Updated 2026-08-13

ANALYST SUMMARY

MannKind Corporation (MNKD) is currently trading at $3.85 with a Wall Street consensus price target of $7.97, implying potential upside of 107.0% over the next 12 months. 8 analysts currently cover MNKD, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $13.0, while the most cautious has a target of $4.75.

MNKD operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 31.3% year-to-date and is currently trading near the lower end of its 52-week range of $2.23 – $6.51.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GTBIF +124.1%
Green Thumb Industries Inc.
$2B · P/E 13.5x · Buy
OMER +140.7%
Omeros Corporation
$992M · P/E 12.0x · Hold
PAHC +33.1%
Phibro Animal Health Corporation
$1B · P/E 14.6x · Hold
INVA +68.2%
Innoviva, Inc.
$2B · P/E 4.8x · Buy
LMAT +33.9%
LeMaitre Vascular, Inc.
$2B · P/E 29.0x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for MNKD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-05-07 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-07 Building track record
Mizuho - Reiterated
Outperform → Outperform 2026-05-07 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-07 31% win rate (48 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-04-28 Building track record
Mizuho - Reiterated
Outperform → Outperform 2026-04-13 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-03-05 Building track record
RBC Capital ↓ Downgrade
Outperform → Sector Perform 2026-02-27 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →